The global continuous renal replacement therapy market was valued at USD 1,356.7 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2023 to 2030. Factors contributing to this growth include the rising incidence of acute kidney injury (AKI), an increase in sepsis cases, the rapid expansion of hospitals and urgent care centers, growing hospital admission rates, and continuous product innovations by leading companies. The American Kidney Fund reports that 37 million Americans are living with kidney disease, and around 807,000 individuals in the U.S. have been diagnosed with kidney failure.

Demand for advanced CRRT devices is a major driver in the market due to improved patient outcomes. The latest CRRT technology allows for comprehensive analysis and response to technical data, significantly enhancing quality assurance. These technological advancements have led to a more precise evaluation of prescription and delivery patterns, positively impacting clinical results. Modern CRRT devices enable automated data collection and use standardized language, facilitating comparisons across institutions. Leading manufacturers have introduced sophisticated CRRT machines incorporating these capabilities, which is expected to further accelerate market growth.

Gather more insights about the market drivers, restrains and growth of the Continuous Renal Replacement Therapy Market

Additionally, the development of specialized CRRT products for pediatric patients is anticipated to boost the market. Traditionally, pediatric CRRT cases have relied on systems designed for adults, which are not specifically licensed for pediatric use, posing potential clinical challenges, especially for neonates. To address these issues, several manufacturers now provide a range of renal care solutions to improve access, outcomes, and quality of life for pediatric patients with severe renal conditions, driving market expansion globally.

According to the American Hospital Association, in 2023, the U.S. had 5,157 community hospitals, 206 federal government hospitals, and 107 other hospitals. An increase in hospital admissions for AKI and a growing elderly population are fueling the demand for CRRT systems. Moreover, the Centers for Disease Control and Prevention (CDC) reported that, as of 2021, approximately 786,000 Americans had end-stage renal disease (ESRD), also known as end-stage kidney disease (ESKD), with 71% on dialysis and 29% with a kidney transplant. In 2020, there were around 7,500 dialysis clinics in the U.S., underscoring the need for CRRT solutions.

Modality Segmentation Insights:

The CRRT market can be segmented into different modalities: slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF). In 2022, the CVVH segment led the market with a revenue share of 31.6%, driven by the high prevalence of fluid overload among AKI patients in critical care settings. Fluid overload, often seen in congestive heart failure cases, significantly impacts dialysis patients. According to an article in Elsevier, congestive heart failure accounted for roughly 5% of all-cause mortality among dialysis patients, a condition closely related to fluid overload. This association is expected to increase demand for CVVH treatment.

The CVVHDF segment is anticipated to grow at the fastest CAGR of 9.2% over the forecast period. CVVHDF, which utilizes a highly effective hemodiafilter, enables the combined removal of fluid and solutes, merging both hemodialysis and hemofiltration techniques. This treatment involves comprehensive fluid and solute clearance from the blood and has become the most commonly used CRRT modality for AKI in various countries. CVVH was the primary CRRT modality until CVVHDF was introduced in 2008, which quickly became the dominant CRRT approach. CVVHDF’s association with higher survival rates relative to other CRRT options is expected to contribute to its rapid market growth in the coming years.

Order a free sample PDF of the Continuous Renal Replacement Therapy Market Intelligence Study, published by Grand View Research.